Malignant peripheral nerve sheath tumor of the vulva, an unusual differential diagnosis for vulvar mass

Bülent Özdal1, Murat Öz, Elmas Korkmaz2, Ömür Ataoğlu3, Tayfun Güngör4
1 Department of Gynecological Oncology, Zekai Tahir Burak Women’s Health Hospital, Ankara, Turkey
2 Department of Pathology, Mikro-pat, Ankara, Turkey

ABSTRACT

INTRODUCTION: Malignant peripheral nerve sheath tumors (MPNSTs) are rare, up to one half of the MPNSTs occur in patients with neurofibromatosis type-1 (NF-1), while the rest are sporadic. Here, we present a 52-year-old woman with MPNST of the vulva without NF-1. We will discuss basics of the disease, treatment options and follow-up strategies.

PRESENTATION OF CASE: 52-year-old female admitted to our hospital with complaint of abnormal uterine bleeding and rapidly growing vulvar mass. Excisional biopsy of the mass showed MPNST of the vulva. Afterwards, the patient underwent radical vulvectomy with inguinofemoral lymph node dissection. Short after the surgery, multiple lung metastasis were shown and responded to chemotherapy, but rapid local recurrence occurred short after the completion of the chemotherapy.

DISCUSSION: The primary treatment option in MPNSTs is surgical excision with or without adjuvant therapy. There is not enough data about the role of systemic chemotherapy in the management of MPNSTs and it still remains controversial.

CONCLUSION: In general, radiation therapy has not been demonstrated to improve overall survival. Complete surgical resection of the primary tumor is the mainstay of the treatment.

© 2014 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).

1. Introduction

Malignant peripheral nerve sheath tumors (MPNSTs) are rare; MPNST of the vulva is extremely rare and devastating tumor. Up to one half of the MPNSTs occur in patients with neurofibromatosis type-1 (NF-1), while the rest are sporadic.1

Optimal treatment of MPNST is surgical resection of the tumor with adequate clear margins, if it is not possible adjuvant radiation therapy with or without chemotherapy may be necessary. Management of locally advanced tumors is challenging and the prognosis is poor. Poor prognostic factors are: tumor size larger than 5 cm, high tumor grade, coexistence with NF-1, advanced patient age, distant metastasis and inability to achieve tumor free margins at the initial surgery.2

Here, we present a 52-year-old woman with MPNST of the vulva without NF-1. We will discuss basics of the disease, treatment options and follow-up strategies.

2. Case report

A 52-year-old woman admitted to our hospital’s gynecology department with abnormal uterine bleeding and rapidly growing vulvar mass in the left labium majus. The physical examination of the patient was completely normal without any stigmata of NF-1. Hemoglobin levels and serum biochemical parameters were in normal range. Trans-vaginal ultrasound revealed multiple intramural and submucous leiomyomas with normal adnexa. The mass in the left labium majus was semi-mobile and 5 cm in diameter.

A total abdominal hysterectomy and bilateral salpingo-oophorectomy was performed for uterine leiomyomas and abnormal vaginal bleeding. Afterwards, the vulvar mass was excised and sent for frozen section pathology. Frozen section result was not precise for diagnosis and it is indicated that final diagnosis could be made with paraffin sections.

Paraffin section result for the tumor was high-grade sarcoma with myxoid areas and epithelial component and spindle cells with tumor positive surgical margins. The tumor had high mitotic activity, that, 10 to 15 mitotic figures were seen per 10 high-power field.

http://dx.doi.org/10.1016/j.ijscr.2014.09.006
2120-2612© 2014 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Large areas of epithelioid cells (Fig. 1) and clusters of wavy spindle cells (Fig. 2) were present. Tumor cells were positive for S-100 and negative for cytokeratin, CEA and EMA (Fig. 3). Uterus and adnexa were normal except large and multiple myomas. The patient was referred to our gynecologic oncology department two weeks after the initial surgery. Vulvar mass had grown to 6 × 3 cm in the two weeks. No distant metastases were noted in thoraco-abdomino-pelvic computerized tomography scans. Radical vulvectomy with bilateral inguino-femoral lymph node dissection was performed. Final pathology was consistent with MPNST of the vulva. All dissected lymph nodes, total of 17, were negative for tumoral involvement. 6 cycles of adjuvant Ifosfamide, Mesna and Adriamycin (IMA) combination chemotherapy was planned. The patient was discharged from the hospital after 5 days of uneventful post-operative course.

Three weeks after the radical vulvectomy, just before the first cycle of chemotherapy, thorax CT revealed multiple metastatic nodules in the lungs. After the third chemotherapy cycle, thorax CT showed rapid response to the therapy, all metastatic nodules were disappeared. After the completion of the sixth cycle, the patient complained about pelvic pain. Pelvic CT showed tumoral invasion of the iliac bones. Palliative radiation therapy was planned for severe pain.

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

3. Discussion

The incidence of MPNST in the general population is 1 per 1 million people per year; the most common localizations for MPNSTs are extremities, trunk, head and neck. Less than 1% of all MPNSTs are located in the vulva. MPNSTs are locally aggressive and tend to recur or metastasize after surgical excision\(^1\) and even with aggressive surgical and radiation treatment, the prognosis is not good.\(^2,3\) In the literature, five-year survival is between 34 and 64 percent.\(^2,4\)

Microscopic features of MPNSTs are varied as they originate from schwann cells, the pluripotential cells of neural crest.\(^5\) The tumor cells show positive staining for S-100, negative staining for cytokeratin, actin smooth muscle, HMB45 and alpha-1 antitrypsin.\(^6\) Microscopic findings of our case were clusters of wavy spindle cells, epithelioid cells on the background, that showing myxoid changes. Tumor cells showed neural and vascular invasion. Microscopic findings of vulvar MPNSTs in the literature are quite similar with our case. The most common findings are wavy spindle cells and epithelioid cells. High mitotic activity and coagulative necrosis are typically present in high-grade tumors.

The most presenting symptom of the disease is rapid growing mass and often accompanied by pain.\(^7\) MPNST rising from female external genitalia is extremely rare. The median age of patients with MPNST of the vulva is 40 years in the literature.\(^8\)

The primary treatment option is surgical excision with or without adjuvant therapy. If complete surgical excision is difficult to achieve, then neo-adjuvant radiotherapy or chemotherapy may be an appropriate option. The most predictive factor for survival seems to be complete resection of the tumor with clear surgical margins. There are only 12 reported cases on MPNST of the vulva in the literature. Due to rarity of the condition, there is no consensus about optimal treatment or adjuvant therapy strategies. Most of the cases had undergone wide local excision without further adjuvant therapy. Only three patients of vulvar MPNST had undergone radical vulvectomy with lymph node dissection\(^9,10\) as our case. There were no nodal involvement in our case and there is not enough data in the literature about necessity of lymph node dissection in MPNST because disease spread seems to be hematogenous rather than lymphatic way.
There is not enough data about the role of systemic chemotherapy in the management of MPNSTs and it still remains controversial.\textsuperscript{11} Adjuvant therapy after initial surgery in high-risk patients and neo-adjuvant therapy in patients who have large, unresectable or metastatic disease may be useful for systemic and local control of the disease. The most studied regimen for MPNST is Ifosfamide and Adriamycin (Doxorubicin) based regimens. Based on these information we planned 6 cycles of adjuvant IMA combination chemotherapy.

MPNSTs have been demonstrated to have high local recurrence rates. Terada et al.\textsuperscript{10} advocated that radiotherapy is ineffective as primary therapy, but Lambrou et al.\textsuperscript{2} showed utility of neo-adjuvant radiation therapy in a recurrent large MPNST of the vulva. In general, radiation therapy has not been demonstrated to improve overall survival in patients with MPNST, but it is shown that adjuvant radiation therapy improves local control of the disease.\textsuperscript{12}

Local recurrence rate of MPNSTs following surgical resection ranges 20–40% and local recurrences tend to occur short after initial resection. The most important risk factor for recurrence is incomplete resection and positive surgical margins. Significant number of patients with MPNST tend to have metastatic disease at the time of diagnosis. Lungs are the most common site for distant metastasis. The natural prognosis of MS is poor, in addition to this; recurrent and metastatic disease, large tumor size and incomplete resection are related with poorer prognosis.

MPNSTs remain a diagnostic and therapeutic challenge. Complete surgical resection of the primary tumor is the mainstay of the treatment and additional treatment options such as chemotherapy and radiation therapy warrants local and distant control of the disease.

**Conflicts of interest**

The authors have no conflict of interest to disclose.

**Funding**

None.

**Ethical approval**

We have obtained detailed written informed consent from the patient.

**Author contributions**

Bulent Ozdal contributed to the surgical intervention and writing the manuscript. Murat Oz contributed to the surgical intervention, literature review and writing the manuscript. Elmas Korkmaz contributed to surgical intervention and literature review. Omur Ataoglu contributed to the pathological study and data collection. Tayfun Gungor and Mehmet M. Meydanli contributed to study design, discussion and supervision.

---

**Key learning points**

- Clinical diagnosis, surgical management and adjuvant therapy options for malignant peripheral nerve sheath tumor (MPNST) of the vulva.
- MPNSTs are extremely malignant and have high potential for local recurrence.
- The prognosis depends on complete resection of the tumor with clear surgical margins.

**References**

1. Ducatman BS, Scheithauer BW, Pieggras DG, Reiman HM, Llistrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. *Cancer* 1986;57(10):2006–21.
2. Stucky CC, Johnson KN, Gray RJ, Pockaj BA, Ocal IT, Rose PS, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. *Ann Surg Oncol* 2012;19(3):878–85.
3. Doorn FF, Molenaar WM, Butes J, Hoekstra HJ. Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis. *Eur J Surg Oncol* 1995;21(1):78–82.
4. Kolberg M, Holand M, Agiesen TH, Brekke HR, Liestol K, Hall KS, et al. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumors patients with and without neurofibromatosis type 1. *Neuro-oncology* 2013;15(2):135–47.
5. Woodruff JM. Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis. *Am J Med Gen* 1999;89(1):23–30.
6. Maglione MA, Tricario OD, Calandrila L. Malignant peripheral nerve sheath tumor of the vulva. A case report. *J Reprod Med* 2002;47(9):721–4.
7. Lambrou NC, Mirhashemi R, Wolfson A, Thesiger P, Penalver M. Malignant peripheral nerve sheath tumor of the vulva: a multimodal treatment approach. *Gynecol Oncol* 2002;85(2):365–71.
8. Lee YS, Choi YJ, Kang CS, Kang SJ, Kim BK, Shim SI. Purely epithelioid malignant peripheral nerve sheath tumor of the vulva. *J Korean Med Sci* 1997;12(1):78–81.
9. DiSaia PJ, Rutledge F, Smith JP. Sarcoma of the vulva. Report of 12 patients. *Obstet Gynecol* 1971;38(2):180–4.
10. Terada KY, Schmidt BW, Roberts JA. Malignant schwannoma of the vulva. A case report. *J Reprod Med* 1988;33(12):969–72.
11. Grobmyer SR, Reith JD, Shahlaee A, Bush CH, Hochwald SN. Malignant peripheral nerve sheath tumor: molecular pathogenesis and current management considerations. *J Surg Oncol* 2008;97(4):340–9.
12. Carli M, Ferrari A, Mattke A, Zanetti I, Casanova M, Bisogno G, et al. Pediatritic malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. *J Clin Oncol* Off J Am Soc Clin Oncol 2005;23(3):8422–30.